

Gene Therapy Solutions

Innovative program helps employers mitigate costs of gene therapy treatment

Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for treating or curing disease. Developments in gene and cell therapies have the potential to provide life-changing treatments, but also present a significant financial risk to self-funded plan sponsors and employers.

Amwins Gene Therapy Solutions is available exclusively through Stealth Partner Group, a leading provider of stop-loss solutions that brings unrivaled knowledge and expertise in helping employer groups mitigate their financial risk. This cost-containment program when coupled with stop-loss coverage provides a sustainable, evolutionary strategy that prepares employers to face unexpected, high-dollar gene therapy claims with confidence.

Program Advantages

Meaningful Protection: Offering first-dollar protection to the plan sponsor

Portability: Changing carriers without disrupting program terms

Seamless Contract Management: Eliminating an additional layer of complexity by managing contract terms

Simplified Billing: Reducing administrative burden by including the program fee in the stop-loss bill

Navigating the Future Landscape of Gene Therapy



There are 27 cellular and gene therapies in the market today:

- 21 cellular treatments
- 6 gene therapy treatments
- Gene therapy treatments range in price from \$800,000 - \$3,500,000.
- We predict there will be an additional 7-10 treatments approved by the end of 2023
- The cost of the therapies are expected to continue to rise.

Source: [Approved Cellular and Gene Therapy Products | FDA](#)

Program details*:

Covered Pharmaceuticals	Covered Diseases	Maximum Payable Per Covered Person Per Agreement Year	Cost of Program
- Luxturna	Leber Congenital Amaurosis (LCA) hereditary blindness	\$850,000	\$1.00 per employee per month (PEPM)
- Zolgensma - Spinraza**	Spinal Muscular Atrophy (SMA) Type 1 and Type 2	\$2,200,000	

* Program disbursements are subject to coverage terms and exclusions.

**Amwins Gene Therapy Solutions addresses Spinal Muscular Atrophy as a disease state. While Spinraza is not classified as a gene therapy treatment, it is a Chronic Specialty Therapy for patients with SMA. Spinraza is costly, with the initial treatment expense of \$750,000 and an additional \$375,000 expected annually. We include Spinraza in our program to help reduce this financial burden.